

The Hunningue Biotechnology Center

Innovating for patients

Launched in 2005, the Hunningue production facility is a global leader in monoclonal antibodies manufacturing. More than 700 highly qualified men and women work here producing innovative, complex biopharmaceuticals across a diversity of therapeutic areas, including dermatology, immunology, and respiratory diseases. These treatments can significantly improve the daily lives of patients.



We are looking for candidates ready for a challenge! Find all our job offers here: www.novartis.com/careers or flash the QR code.



OUR AMBITIONS

- **To guarantee clinical and commercial production** of pharmaceuticals for patients around the world, with the highest levels of quality
- **To build and encourage a culture** in which each employee feels comfortable, safe, empowered, and proud to be part of 'Made in Hunningue'



“At Novartis, our mission is to provide patients worldwide with innovative medicine that give them hope for the future. To achieve these ambitions we continually invest to strengthen our

production capacity and modernize our facilities. In addition to our state of the art facilities, our ability to manufacture products to uncompromising levels of quality and safety relies on the commitment and passion of the teams who drive innovation forward on an everyday basis for the benefit of patients..”

Paula Rosa – Hunningue Site Head

KEY DATA



4 BIOPHARMACEUTICALS
manufactured using cell culture technology



3 PRODUCTION UNITS
working 24/7



150 MILLION EUROS
invested to launch a new production line in 2020



8 BIOREACTORS
of cell culture of 15 000L each



18+ NATIONALITIES
represented in this facility



2025 CARBON NEUTRAL

Flash this code to find out more

